Home › Merck Receives FDA Approval for ISENTRESS (raltegravir) for Pediatric Oral Suspension
 

Keywords :   


Merck Receives FDA Approval for ISENTRESS (raltegravir) for Pediatric Oral Suspension

2014-01-08 14:30:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) recently approved ISENTRESS for oral suspension, a new pediatric formulation of Mercks integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients four weeks of age and older. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: approval oral receives suspension

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
25.06Royal Mail buyer to make offer for all staff shares
25.06Hybrid Software wins FLAG Vendor Partner of the Year award
25.06Hospeco Purchases Nuance Solutions
25.06Atlantic Tropical Weather Outlook
25.06DNA Genetics opens new commercial sow research farm
25.06Eastern North Pacific Tropical Weather Outlook
25.06Briolf Group to Invest $30 Million in Its First US Production Plant
25.06IDENTCO rebrands TTL200 Series to DuraWrap and DuraFlag
More »